0
Department of Veterans Affairs Awarded a Contract to GLENMARK PHARMACEUTICALS INC., USA for $2,635,810.00
Signed on
9/2/2020, 12:00 AM
GLENMARK PHARMACEUTICALS INC., USA Government Contract #36E79720D0068
GLENMARK PHARMACEUTICALS INC., USA was awarded a contract with the United States Government for $2,635,810.00. The contract was awarded by the agency office NAC PHARMACEUTICALS (36E797), which is a division with the Department of Veterans Affairs within the Department of Veterans Affairs.
Summary of Award
The U.S. federal government issued an indefinite delivery/requirements (IDV) contract to Glenmark Pharmaceuticals Inc., USA, with an award ID of "36E79720D0068." This contract, which signifies a commitment by the U.S. Department of Veterans Affairs (VA), specifically aims to provide Aprepitant Capsules over a set period commencing from November 1, 2020, and lasting until October 31, 2021, with provisions for four one-year extensions. This contract type is particularly advantageous in its flexibility, enabling the government to adjust the quantities required as per ongoing needs without committing to a fixed amount upfront. This approach ensures that resources are allocated as necessary, safeguarding against overproduction and waste.
Glenmark Pharmaceuticals Inc., USA, based in Mahwah, New Jersey, serves as the contract recipient. This company operates under its parent entity, Glenmark Pharmaceuticals Limited, and is categorized as a foreign-owned, U.S.-incorporated business entity. Glenmark Pharmaceuticals is prominently involved in pharmaceutical preparation manufacturing, a sector characterized by the production of medicinal drugs and biologicals. Against this backdrop, the company offers a substantial portfolio of pharmaceutical products, including specific therapeutic drugs like Aprepitant, which is used to prevent nausea and vomiting caused by chemotherapy.
The awarded contract has a total potential ceiling value of $2,635,810, a figure reflecting the upper financial limit across the contract's lifespan, should all optional extensions be enacted. However, it should be noted that the initial obligation by the U.S. government is capped at $0, indicating a reliance on the contract’s nature, which allows for purchases as needed. This aligns with the IDV contract type, which offers flexibility in procurement without immediate financial commitment. Despite the absence of a specified total obligation, as of the last update, the contract’s structure ensures that all necessary resources are made available to fulfill its designated purpose.
Transactions linked with this contract delineate various notable points and modifications, captured through multiple actions dated across several years. Each transaction bears the hallmark of the indefinite delivery/requirements contract type and involves zero-value monetary exchanges, adhering to the contract’s predefined parameters. The contract's enduring purpose is to cater to the evolving pharmaceutical needs of the VA, ensuring continuous supply for the duration of its terms or extensions.
Each modification, ranging from “P00001” to “P00017,” reflects a distinct transaction or administrative amendment, with corresponding action dates from the contract's initiation in 2020 to 2025. These modifications function as sequential updates ensuring that the scope of the contract remains relevant and aligned with federal requirements. Importantly, these transactions do not indicate additional financial obligations beyond the original terms. Instead, they represent routine adjustments or administrative changes which are regular features in extensive contracts of this nature.
The Department of Veterans Affairs acts both as the funding and awarding agency, highlighting a cohesive internal structure aimed at optimizing procurement processes while ensuring the continuous availability of pharmaceutical supplies. The sub-agency overseeing this contract, NAC Pharmaceuticals (36E797), falls within the VA's jurisdiction and is tasked with maintaining the contract’s logistical and operational aspects. This alignment underscores the VA’s strategic focus on efficiently managing supply chains pertinent to healthcare delivery services for veterans.
Glenmark Pharmaceuticals, well-versed in pharmaceutical manufacturing, is entrusted with delivering Aprepitant Capsules through this contract. Aprepitant is vital in managing chemotherapy-induced nausea, thereby playing a crucial role in cancer treatment protocols supplied to VA healthcare facilities. The company’s expertise and compliance with commercial product and service standards are pivotal, ensuring adherence to the firm-fixed price terms delineated in the contract.
Furthermore, the contract's execution benefitted from open competition principles, providing an opportunity for multiple contenders. However, with only two offers received, Glenmark Pharmaceuticals emerged as the sole awardee, reinforcing the company's competitive standing and capability to meet federal procurement needs effectively.
In summary, the awarded contract between the U.S. federal government and Glenmark Pharmaceuticals Inc., USA represents a strategic partnership focused on the continuous supply of critical pharmaceutical products within a flexible procurement framework. This herculean task involves meticulous coordination, adherence to regulatory standards, and judicious financial oversight, collectively ensuring that the VA's pharmaceutical supply needs are met efficiently, supporting the well-being of veterans nationwide.
Contract Details
Agency Details
Recipient Details
Comments
Award Transactions
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.
Department of Veterans Affairs, a sub agency of Department of Veterans Affairs, issued a payment of $0.00 to GLENMARK PHARMACEUTICALS INC., USA. The payment included a Subsidy Cost of $0.00.
This payment could indicate a change to the existing contract.